These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37624749)

  • 21. Peripheral blood mononuclear cells - Can they provide a clue to the pathogenesis of Graves' Orbitopathy?
    Basak M; Sanyal T; Kar A; Bhattacharjee P; Das M; Chowdhury S
    Endocrine; 2022 Feb; 75(2):447-455. PubMed ID: 34545512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
    Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
    Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of ibrutinib on inflammation in a mouse model of Graves' orbitopathy.
    Kim C; Park JH; Choi YJ; Jun HO; Chung JK; Park TK; Yoon JS; Yang JW; Jang SY
    Front Endocrinol (Lausanne); 2024; 15():1420024. PubMed ID: 39280007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Animal models of Graves' disease and Graves' orbitopathy.
    Nagayama Y; Nakahara M; Abiru N
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):381-6. PubMed ID: 26181432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 26. Preclinical models of Graves' disease and associated secondary complications.
    Moshkelgosha S; So PW; Diaz-Cano S; Banga JP
    Curr Pharm Des; 2015; 21(18):2414-21. PubMed ID: 25777757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Graves' hyperthyroidism: present and future.
    Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment and Comparison of Two Different Animal Models of Graves' Orbitopathy.
    Wang W; Zhang JW; Qin YJ; Li HY; Dai YX; Li H
    Transl Vis Sci Technol; 2023 Jun; 12(6):12. PubMed ID: 37342053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
    Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
    J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.
    Yin X; Latif R; Bahn R; Tomer Y; Davies TF
    Thyroid; 2008 Nov; 18(11):1201-6. PubMed ID: 18925838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves' disease.
    McLachlan SM; Rapoport B
    Endocrine; 2019 Nov; 66(2):137-148. PubMed ID: 31560118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Mouse Thyrotropin Receptor A-Subunit Transgene Expressed in Thyroiditis-Prone Mice May Provide Insight into Why Graves' Disease Only Occurs in Humans.
    McLachlan SM; Aliesky HA; Rapoport B
    Thyroid; 2019 Aug; 29(8):1138-1146. PubMed ID: 31184281
    [No Abstract]   [Full Text] [Related]  

  • 33. An improved Graves' disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice.
    Kaneda T; Honda A; Hakozaki A; Fuse T; Muto A; Yoshida T
    Endocrinology; 2007 May; 148(5):2335-44. PubMed ID: 17255207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of Mouse Models of Graves' Disease and Orbitopathy-Novel Treatment by Induction of Tolerance.
    Ungerer M; Faßbender J; Li Z; Münch G; Holthoff HP
    Clin Rev Allergy Immunol; 2017 Apr; 52(2):182-193. PubMed ID: 27368808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling Graves' Orbitopathy in Experimental Graves' Disease.
    Banga JP; Moshkelgosha S; Berchner-Pfannschmidt U; Eckstein A
    Horm Metab Res; 2015 Sep; 47(10):797-803. PubMed ID: 26287396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyrotropin receptor antibodies and Graves' orbitopathy.
    Diana T; Ponto KA; Kahaly GJ
    J Endocrinol Invest; 2021 Apr; 44(4):703-712. PubMed ID: 32749654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy with a biologically active ICAM-1 mAb and an siRNA targeting TSHR in a BALB/c mouse model of Graves' disease.
    Wang X; Liu W; Rui Z; Zheng W; Tan J; Li N; Yu Y
    Endokrynol Pol; 2021; 72(6):592-600. PubMed ID: 34647608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human placenta-derived mesenchymal stem cells ameliorate orbital adipogenesis in female mice models of Graves' ophthalmopathy.
    Park M; Banga JP; Kim GJ; Kim M; Lew H
    Stem Cell Res Ther; 2019 Aug; 10(1):246. PubMed ID: 31399042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy.
    Yin X; Latif R; Bahn R; Davies TF
    Thyroid; 2012 Jul; 22(7):730-6. PubMed ID: 22663548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TSH receptor specific monoclonal autoantibody K1-70
    Furmaniak J; Sanders J; Sanders P; Li Y; Rees Smith B
    Clin Endocrinol (Oxf); 2022 Jun; 96(6):878-887. PubMed ID: 35088429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.